Weber H C, Venzon D J, Jensen R T, Metz D C
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Gastroenterology. 1997 Jan;112(1):84-91. doi: 10.1016/s0016-5085(97)70222-1.
BACKGROUND & AIMS: The interrelation between Helicobacter pylori infection and proton pump inhibitor therapy in patients with Zollinger-Ellison syndrome is unknown. The aim of this study was to evaluate the influence of these factors on parameters of Zollinger-Ellison syndrome.
Prevalence of H. pylori was determined by biopsy and antibody testing in 84 patients. The influence of H. pylori status on clinical and laboratory parameters of Zollinger-Ellison syndrome was evaluated. Seroconversion after surgery was assessed retrospectively in infected patients.
The prevalence of H. pylori exposure was 23% (10% with active infection). Acid output was higher in H. pylori-negative patients, but other clinical and biochemical parameters did not differ. Parameters were also similar for patients determined to be H. pylori positive by histology or antibody testing alone. Seroconversion rates did not differ between those rendered or not rendered disease free despite a significant reduction in acid output.
H. pylori infection is not a risk factor for peptic ulceration in patients with Zollinger-Ellison syndrome. The prevalence is lower than in the general population and much lower than for patients with idiopathic peptic ulcer disease. Long-term omeprazole therapy in H. pylori-positive patients with Zollinger-Ellison syndrome may-lead to a reduction in parietal cell mass.
胃泌素瘤患者中幽门螺杆菌感染与质子泵抑制剂治疗之间的相互关系尚不清楚。本研究旨在评估这些因素对胃泌素瘤综合征各项参数的影响。
通过活检和抗体检测确定了84例患者中幽门螺杆菌的感染率。评估了幽门螺杆菌感染状态对胃泌素瘤综合征临床和实验室参数的影响。对感染患者术后的血清转化情况进行了回顾性评估。
幽门螺杆菌感染率为23%（10%为现症感染）。幽门螺杆菌阴性患者的胃酸分泌量较高，但其他临床和生化参数并无差异。仅通过组织学或抗体检测确定为幽门螺杆菌阳性的患者，其各项参数也相似。无论胃酸分泌量是否显著降低，达到或未达到疾病缓解的患者血清转化率并无差异。
幽门螺杆菌感染并非胃泌素瘤综合征患者发生消化性溃疡的危险因素。其感染率低于普通人群，远低于特发性消化性溃疡疾病患者。幽门螺杆菌阳性的胃泌素瘤综合征患者长期使用奥美拉唑治疗可能会导致壁细胞数量减少。
